SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro

ACS Chem Neurosci. 2024 Jan 17;15(2):215-221. doi: 10.1021/acschemneuro.3c00468. Epub 2023 Dec 22.

Abstract

Since the SARS-CoV-2 virus started spreading worldwide, evidence pointed toward an impact of the infection on the nervous system. COVID-19 patients present neurological manifestations and have an increased risk of developing brain-related symptoms in the long term. In fact, evidence in support of the neuroinvasive potential of SARS-CoV-2 has emerged. Considering that viral parkisonism was observed as a consequence of encephalopathies caused by viral infections, it has been already suggested that COVID-19 could affect the dopaminergic neurons and contribute to neurodegeneration in Parkinson's disease (PD), by promoting the formation of amyloid fibrils constituted by the PD-related protein α-synuclein. Here, we observe not only that SARS-CoV-2 viral spike protein and nucleocapsid protein can alone promote α-synuclein aggregation but also that the spike protein organization in a corona shape on the viral envelope may be crucial in triggering fast amyloid fibrils formation, thus possibly contributing to PD pathogenesis.

Keywords: COVID-19; Parkinson’s disease; aggregation; coronavirus; spike; α-synuclein.

MeSH terms

  • COVID-19*
  • Humans
  • Parkinson Disease* / metabolism
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • alpha-Synuclein / metabolism

Substances

  • alpha-Synuclein
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2